Cargando…

Successful Treatment of New-Onset Pediatric Nephrotic Syndrome With Rituximab as a First-Line Therapy

Detalles Bibliográficos
Autores principales:	Zhang, Xiaojing, Jin, Yanyan, Li, Qiuyu, Xie, Yi, Liu, Fei, Huang, Guoping, Chen, Junyi, Fu, Haidong, Wang, Jingjing, Shen, Huijun, Mao, Jianhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727513/ https://www.ncbi.nlm.nih.gov/pubmed/36506238 http://dx.doi.org/10.1016/j.ekir.2022.10.016

Ejemplares similares

COVID-19 Breakthrough Infections in Vaccinated Kidney Transplant Recipients
por: Zhang, Xiaojing, et al.
Publicado: (2022)

Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome
por: Fenoglio, Roberta, et al.
Publicado: (2018)

Benefits and risks of essential trace elements in chronic kidney disease: a narrative review
por: Xie, Yi, et al.
Publicado: (2022)

Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome
por: Yamazaki, Mayuko, et al.
Publicado: (2019)

Successful desensitization to high dose rituximab for a child with nephrotic syndrome – The first report in the literature
por: Kakleas, Konstantinos, et al.
Publicado: (2021)

Successful Pregnancies in a Patient with Childhood-onset Steroid-dependent Nephrotic Syndrome during Rituximab Maintenance Therapy
por: Nara, Mizuho, et al.
Publicado: (2021)

Rituximab for nephrotic syndrome in children
por: Iijima, Kazumoto, et al.
Publicado: (2016)

Pediatric membranous nephropathy: In the novel antigens era
por: Huang, Guoping, et al.
Publicado: (2022)

Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome
por: Counsilman, Clare E., et al.
Publicado: (2015)

CCL22 and Leptin associated with steroid resistance in childhood idiopathic nephrotic syndrome
por: Zhaoyang, Peng, et al.
Publicado: (2023)

Rituximab Treatment for Nephrotic Syndrome in Children
por: Iijima, Kazumoto, et al.
Publicado: (2014)

Effectiveness of rituximab in nephrotic syndrome treatment
por: Popko, Katarzyna, et al.
Publicado: (2017)

Efficacy of Triptolide for Children with Moderately Severe Henoch-Schönlein Purpura Nephritis Presenting with Nephrotic Range Proteinuria: A Prospective and Controlled Study in China
por: Wu, Li, et al.
Publicado: (2013)

Rituximab therapy for childhood onset idiopathic nephrotic syndrome: experience of a Portuguese tertiary center
por: Gomes, Rita, et al.
Publicado: (2022)

Rituximab Use in the Management of Childhood Nephrotic Syndrome
por: Kallash, Mahmoud, et al.
Publicado: (2019)

Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome
por: Chen, Yewei, et al.
Publicado: (2021)

Rituximab Use for the Treatment of Childhood Nephrotic Syndrome by Canadian Pediatric Nephrologists: A National Survey
por: Meeuwisse, Cory, et al.
Publicado: (2022)

Rituximab therapy in adults with steroid-dependent nephrotic syndrome
por: Zhong, Hongzhen, et al.
Publicado: (2019)

Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome
por: Angeletti, Andrea, et al.
Publicado: (2022)

Rituximab May Have Positive Effect on Refractory Nephrotic Syndrome: A Meta-Analysis of Randomized Trials
por: Lin, Jingjing, et al.
Publicado: (2022)

Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura
por: Chen, Haifei, et al.
Publicado: (2017)

Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura
por: Nishikawa, Mana, et al.
Publicado: (2019)

Rituximab in idiopathic nephrotic syndrome: still waiting for stronger evidences
por: Belangero, Vera Maria Santoro
Publicado: (2023)

Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease
por: Iwabuchi, Yuko, et al.
Publicado: (2018)

New-onset pediatric idiopathic nephrotic syndrome secondary to COVID-19
por: Takagi, Yuhi, et al.
Publicado: (2023)

Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea
por: Ahn, Yo Han, et al.
Publicado: (2018)

Successful Treatment of Recalcitrant Pediatric Pemphigus Vulgaris With Rituximab
por: Santiago-Vázquez, Marely, et al.
Publicado: (2022)

Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital
por: Bazargani, Behnaz, et al.
Publicado: (2022)

Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report
por: Zhang, Xiaojing, et al.
Publicado: (2021)

Distress in parents of children with first-onset steroid-sensitive nephrotic syndrome
por: Veltkamp, Floor, et al.
Publicado: (2023)

The important roles and molecular mechanisms of annexin A(2) autoantibody in children with nephrotic syndrome
por: Ye, Qing, et al.
Publicado: (2021)

Rituximab is not a “magic drug” in post-transplant recurrence of nephrotic syndrome
por: Grenda, Ryszard, et al.
Publicado: (2016)

Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials
por: Iijima, Kazumoto, et al.
Publicado: (2017)

The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective
por: Maratea, Dario, et al.
Publicado: (2016)

A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome
por: Xu, Jing, et al.
Publicado: (2021)

Hypokalemia after rituximab administration in nephrotic syndrome: two case reports
por: Song, Yiyun, et al.
Publicado: (2023)

Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
por: Hogan, Julien, et al.
Publicado: (2020)

Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children
por: Longoni, Giulia, et al.
Publicado: (2014)

Successful treatment of adult-onset collapsing focal segmental glomerulosclerosis with rituximab
por: Ramachandran, Raja, et al.
Publicado: (2013)

Severe vaso-occlusive lupus retinopathy in the early stage of a pediatric patient with systemic lupus erythematosus: a case report
por: Huang, Guoping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e57kd7nofhqvn1oq6fd51uv4ju